Browsing Tag
Acrux Limited
2 posts
Acrux (ASX: ACR) secures clearer FDA Phase III pathway for female testosterone treatment
Acrux has received formal FDA feedback defining the Phase III clinical development requirements for Female Testosterone MDTS, potentially supporting a future United States registration application while leaving trial funding, safety evidence and commercial partnerships unresolved.
Is Acrux Limited (ACR) quietly turning Lenzetto into a bigger ASX microcap catalyst?
Find out how Acrux Limited’s Lenzetto Australia licensing deal could reshape its ASX microcap story and women’s health strategy today!